ThrEDs - A new regenerative, engineerable modality for reversing fibrosis
ThrEDs are thrombospondin rich particles with a core of ECM proteins that have been demonstrated to reverse fibrotic phenotypes in wound healing and Dupuytren's disease, by engaging both cellular and ECM targets.
Applications: Antifibrotic therapeutics, wound healing, tissue regeneration, targeted drug delivery, engineered nanoparticles
| Features | Benefits |
|---|---|
| Reverses fibrotic cellular phenotypes | Disease-modifying treatment for fibrosis rather than merely slowing progression |
| Acts on both cells and the extracellular matrix | Targets multiple drivers of fibrosis to promote restoration of tissue homeostasis |
| Accelerates cellular migration and wound closure | Enhance tissue repair and regenerative processes |
| Genetically engineerable protein shell | Enables development of customised, targeted therapeutic nanoparticles |
| Naturally occurring, non-vesicular nanoparticle structure | Offers a differentiated therapeutic platform with established laboratory isolation methods |
Patented and Available For
- Co-development
- Consulting
- Licensing